Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cidara Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Cidara Therapeutics, Inc.

CDTX

Cidara Therapeutics, Inc.

About Cidara Therapeutics, Inc.

Cidara Therapeutics is a biotechnology company focused on developing innovative drug-Fc conjugate immunotherapies targeting serious diseases. Its core platform, Cloudbreak, creates long-acting, potent therapies for viral infections like influenza and solid tumors, leveraging dual mechanisms of disease prevention and immune engagement. The company’s key products include CD388 for influenza prophylaxis and CBO421 for cancer, aiming to improve treatment efficacy and resistance profiles through proprietary, targeted biologics.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Cidara Therapeutics, Inc.

1
1
Cidara Therapeutics, Inc. Cidara Therapeutics Reports No Revenue and $83.2 Million Net Loss for Q3 2025

Via official filing (AI summary) | 8 months ago | 0 comments

2
1
Cidara Therapeutics, Inc. Cidara Therapeutics Reports Financial Developments and Strategic Focus on CD388

Via official filing (AI summary) | 11 months ago | 0 comments

3
1
Cidara Therapeutics, Inc. Cidara Therapeutics Reports Increased Losses and Operating Expenses in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Cidara Therapeutics, Inc. Cidara Therapeutics Reports $169.8 Million Net Loss and Decreased Collaboration Revenue in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments